myeloma in English
Multiple myeloma is a hematological malignant neoplasm of the bone marrow.
Use "myeloma" in a sentence
1. New cancers after Autotransplantations for multiple myeloma
2. Mel Goldstein, 66, American television meteorologist (WTNH), multiple myeloma.
3. A major breakthrough in multiple myeloma research was the recognition of the high degree of Clonal heterogeneity in multiple myeloma and its modulation by
4. Clonality in Multiple Myeloma DANA‐FARBER CANCER INSTITUTE Nikhil C
5. Between 10 and 15% of people who have multiple myeloma develop Amyloidosis
6. AL Amyloidosis is closely related to a type of bone marrow cancer called "myeloma" or "multiple myeloma," another disease in which identical clones of antibody-producing cells grow rapidly
7. BlenREP is a prescription medicine used to treat adults with multiple myeloma who have received at least 4 prior medicines to treat multiple myeloma, and their cancer has come back or did not respond to prior treatment
8. Azidothymidine is effective against human multiple myeloma: a new use for an old drug? Pereira et al
9. In this episode of the “Cure® Talks Cancer” podcast, we’re honoring Multiple Myeloma Awareness Month by speaking with Dr
10. Curcumin Circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model
11. Multiple myeloma (MM) is the most common indication for Autologous hematopoietic stem cell transplantation (HSCT) in North America
12. AWE Technology Platform Actinium-225 conjugated to daratumumabCD38 targeting agent for multiple myeloma: R & D Phase complete
13. Despite new staging criteria, which take into account the viability of a myeloma lesion, positron emission tomography (PET) is not used routinely.
14. In reviewing reports on amyloidosis patients with intestinal pseudo-obstruction[Sentencedict], the patients with multiple myeloma tend to have extensive smooth muscle infiltration.
15. 18 In reviewing reports on amyloidosis patients with intestinal pseudo-obstruction, the patients with multiple myeloma tend to have extensive smooth muscle infiltration.
16. Infusion of T lymphocytes expressing Chimeric antigen receptors (CARs) can produce extraordinary antitumor activity in patients with leukemia, lymphoma, and myeloma
17. 26 This kind of technology is suitable to osteoporotic vertebra compressed fracture,(www.Sentencedict.com) vertebra myeloma and some transferred tumors in vertebras .
18. Bluebird bio and BMS deliver on novel treatment option for adults living with relapsed or refractory multiple myeloma Read more Let's recode the system
19. Researchers conducting the Clonal Evolution research project hope to identify point mutations and baseline Clonal heterogeneity as prognostic markers for multiple myeloma
20. South San Francisco-based Allogene Therapeutics released some early data from its Phase I UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma
21. Alkylating drugs are used to treat brain tumors, melanoma, Hodgkin's disease, Non-Hodgkin's lymphoma, breast cancer, ovarian cancer, neuroblastoma, leukemia, multiple myeloma, retinoblastoma, and prostate cancer
22. Myeloma IgG and its light and heavy polypeptide chains were subjected to isoelectric focusing in a vertical column containing a combined pH and density gradient.
23. Inclusion Criteria: Subjects must have newly diagnosed, untreated, symptomatic (according to the revised CRAB criteria 2014), documented myeloma and have measurable disease (serum M-protein ≥ 1 g/dL (for IgA ≥ 0.5 g/dL) or urine M-protein ≥ 200 mg/24 hours) or in case of oligosecretory myeloma: involved FLC level ≥ 10 mg/dl, provided sFLC ratio is abnormal or in case of Asecretory
24. A 45 year old male patient presented with diffuse alveolar hemorrhage. An Immunoglobulin A (IgA) paraprotein secreting myeloma was found to be the underlying cause.
25. Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly reported in patients with bone metastasis from a variety of solid tumors and disseminated multiple myeloma receiving iv Bisphosphonates therapy
26. The risk of developing Amyloidosis is greater in people who: Are older than 50; Have a chronic infection or inflammatory disease; Have a family history of Amyloidosis; Have multiple myeloma
27. Investigation of the quantitative microcirculation parameters amplitude A and exchange rate constant k21 determined by contrast-enhanced dynamic magnetic resonance imaging (d-MRI) in multiple myeloma (MM).
28. Biography Dr Chari is a Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office.
29. In none of the simultaneously-examined seven cases with Waldenström's macroglobulinaemia were changes found corresponding to those of myeloma nephrosis. In three, however-the histological picture of acute renal failure was evident.
30. What is Agranulocytosis? Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) has been reported by people with multiple myeloma, schizophrenia, high blood pressure, breast cancer, preventive health care
31. Monoclonal Anti-a-Adaptin (AP-2) (mouse IgG2a isotype) is derived from the 100/2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse
32. Cepheus (MMY3019) is an ongoing phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of D-VRd vs bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) for whom transplant is …
33. Monoclonal Anti- β1 and β2-Adaptins (AP-1 & AP-2)(mouse IgG1 isotype) is derived from the 100/1 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse
34. About Amer Assal, MD Amer Assal MD is a board certified medical oncologist and hematologist who specializes in the use of autologous and allogeneic bone marrow stem cell transplantation for the treatment of multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes and …
35. Amer Assal MD is a board certified medical oncologist and hematologist who specializes in the use of autologous and allogeneic bone marrow stem cell transplantation for the treatment of multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes and other bone marrow disorders
36. About Amer Assal Amer Assal MD is a board certified medical oncologist and hematologist who specializes in the use of autologous and allogeneic bone marrow stem cell transplantation for the treatment of multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes and …
37. Cardiorespiratory fitness brings about numerous health benefits, most notably a decrease in risk for cardiovascular disease by 30 to 40 percent, stroke by 20 to 27 percent, type 2 diabetes, and some cancers such as colon cancer, breast cancer, lung cancer, and multiple myeloma cancers
38. Patients with any of the following: evidence of severe or uncontrolled systemic disease, Asecretory myeloma, a known history of infection with human immunodeficiency virus (HIV), serological evidence of active Hepatitis B infection, cardiac abnormalities as mentioned in the protocol, previous allogeneic bone marrow transplant, adrenal gland
39. These three patients with multiple myeloma and ESRD were treated with Alkylating agents and autologous HSCT; each had prolonged infection and developed severe SOS in case 1, very severe SOS in case 2, and moderate SOS in case 3 based on proposed grading of …
40. Anthracin 50mg Injection is effective in the treatment of various cancers including cancer of the breast, ovary, stomach, lung, bowel or rectum, malignant lymphomas (a type of blood cancer of infection-fighting cells of the blood) such as Hodgkin's disease and non-Hodgkin's lymphoma, leukemia (blood cancer), multiple myeloma (a type of blood cancer of infection-fighting cells of the blood).
41. In a particular embodiment, the invention provides a method for determining whether a subject with multiple myeloma is likely to respond to a treatment with a proteasome inhibitor wherein the method comprises the step of performing, on a sample from the subject, a gene expression analysis of a number of N genes selected from the group consisting of the genes NUAK1, ITGB7, AGMAT, TFAP2C, CCDC85A, CLEC7A, TMEM37, RNF144A, and CMPK2, wherein N is at least 2and wherein it is concluded that the subject is likely to respond to a treatment with a proteasome inhibitor in case that at least 2 of said N genes are aberrantly expressed.